Association of chronic kidney disease and cardiovascular disease risk with all-cause mortality: an interaction, joint and mediation analysis in Chinese adults | BMC Public Health
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet (London England). 2017;389(10075):1238–52.
Google Scholar
GBDCKDC. Global, regional, and National burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet (London England). 2020;395(10225):709–33.
GBD 2017 Causes of Death Collaborators. Global, regional, and National age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet (London England). 2018;392(10159):1736–88.
Google Scholar
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan CW, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet (London England). 2018;392(10159):2052–90.
Google Scholar
Gaziano L, Sun L, Arnold M, Bell S, Cho K, Kaptoge SK, Song RJ, Burgess S, Posner DC, Mosconi K, et al. Mild-to-Moderate kidney dysfunction and cardiovascular disease: observational and Mendelian randomization analyses. Circulation. 2022;146(20):1507–17.
Google Scholar
United States Renal Data System. The United States Renal Data System 2022 Annual Data Report. 2022.
Minciunescu A, Genovese L, deFilippi C. Cardiovascular alterations and structural changes in the setting of chronic kidney disease: a review of cardiorenal syndrome type 4. SN Compr Clin Med. 2023;5(1):15.
Google Scholar
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.
Google Scholar
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA, et al. The management of blood cholesterol: A report of the American college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143. /ASPC/NLA/PCNA Guideline on.
House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(6):1304–17.
Nichols GA, Ustyugova A, Déruaz-Luyet A, O’Keeffe-Rosetti M, Brodovicz KG. Health care costs by type of expenditure across eGFR stages among patients with and without diabetes, cardiovascular disease, and heart failure. J Am Soc Nephrology: JASN. 2020;31(7):1594–601.
Google Scholar
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrology: JASN. 2006;17(7):2034–47.
Google Scholar
Wang XR, Zhang JJ, Xu XX, Wu YG. Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2019;41(1):244–56.
Google Scholar
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
Google Scholar
Yan S, Li J, Li S, Zhang B, Du S, Gordon-Larsen P, Adair L, Popkin B. The expanding burden of cardiometabolic risk in China: the China health and nutrition survey. Obes Reviews: Official J Int Association Study Obes. 2012;13(9):810–21.
Google Scholar
Kidney Disease. Improving global outcomes (KDIGO) CKD work group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements 2013(3):1–150.
McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S. Canadian cardiovascular society position statement–recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22(11):913–27.
Google Scholar
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.
Google Scholar
Turin TC, Tonelli M, Manns BJ, Ravani P, Ahmed SB, Hemmelgarn BR. Chronic kidney disease and life expectancy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and transplant association -. Eur Ren Association. 2012;27(8):3182–6.
Google Scholar
Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (London England). 2012;380(9854):1649–61.
Google Scholar
Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London England). 2012;380(9854):1662–73.
Google Scholar
Korhonen PE, Kiiski S, Kautiainen H, Ojanen S, Tertti R. The relationship of kidney function, cardiovascular morbidity, and All-Cause mortality: a prospective primary care cohort study. Journal of general internal medicine 2022.
Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696–707.
Google Scholar
Laffin LJ, Bakris GL. Intersection between chronic kidney disease and cardiovascular disease. Curr Cardiol Rep. 2021;23(9):117.
Google Scholar
Zheng J, Zhang Y, Rasheed H, Walker V, Sugawara Y, Li J, Leng Y, Elsworth B, Wootton RE, Fang S, et al. Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. Int J Epidemiol. 2022;50(6):1995–2010.
Google Scholar
Mok Y, Ballew SH, Matsushita K. Chronic kidney disease measures for cardiovascular risk prediction. Atherosclerosis. 2021;335:110–8.
Google Scholar
Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circul Res. 2023;132(8):1050–63.
Google Scholar
Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017;956:307–25.
Google Scholar
Chen S, Chen Y, Liu X, Li M, Wu B, Li Y, Liang Y, Shao X, Holthöfer H, Zou H. Association of insulin resistance with chronic kidney disease in non-diabetic subjects with normal weight. PLoS ONE. 2013;8(9):e74058.
Google Scholar
Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Ren Physiol. 2016;311(6):F1087–108.
Google Scholar
Vithian K, Hurel S. Microvascular complications: pathophysiology and management. Clin Med. 2010;10(5):505–9.
Google Scholar
Ryu H, Hong Y, Kang E, Kang M, Kim J, Park HC, Oh YK, Chin HJ, Park SK, Jung JY, et al. Comparison of outcomes of chronic kidney disease based on etiology: a prospective cohort study from KNOW-CKD. Sci Rep. 2023;13(1):3570.
Google Scholar
Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. (2011) 2017, 7(1):1–59.
Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–27.
Google Scholar
Pun PH, Goldstein BA, Gallis JA, Middleton JP, Svetkey LP. Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease. Kidney Int Rep. 2017;2(6):1122–31.
Google Scholar
Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol. 2018;33(2):227–38.
Google Scholar
Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Supplement. 2002;80:35–8.
Google Scholar
Cai QZ, Lu XZ, Lu Y, Wang AY. Longitudinal changes of cardiac structure and function in CKD (CASCADE study). J Am Soc Nephrology: JASN. 2014;25(7):1599–608.
Google Scholar
Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344–58.
Google Scholar
Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013;38(2):136–48.
Google Scholar
Ueki K, Sasako T, Okazaki Y, Miyake K, Nangaku M, Ohashi Y, Noda M, Kadowaki T. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99(1):256–66.
Google Scholar
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, Knoll GA, Muntner P, Pecoits-Filho R, Sarnak MJ, et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):559–69.
Google Scholar
de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020;98(4):839–48.
Google Scholar
Kitamura H, Tanaka S, Hiyamuta H, Shimamoto S, Tsuruya K, Nakano T, Kitazono T. Cardiovascular risk factor burden and treatment control in patients with chronic kidney disease: A Cross-Sectional study. Journal of atherosclerosis and thrombosis 2022.
DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319–34.
Google Scholar
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–50.
Google Scholar
Junarta J, Fernandez M, Chung I, Salha A, Klaud Francheska BD, Lowe-Jones R, Sharma R, Firoozi S, Banerjee D. Role of a cardio-renal multi-disciplinary team meeting in managing cardiovascular risk in patients on kidney transplant waitlists. Clin Transplant. 2020;34(11):e14061.
Google Scholar
Lai S, Dimko M, Galani A, Coppola B, Innico G, Frassetti N, Mazzei ED, Mariotti A. Early markers of cardiovascular risk in chronic kidney disease. Ren Fail. 2015;37(2):254–61.
Google Scholar
Stensrud MJ, Hernán MA. Why Test Proportional Hazards? Jama. 2020;323(14):1401–2.
Google Scholar
link
